| Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates |
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.30 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.59 per share a year ago. |
zacks.com |
2025-05-14 13:25:50 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update |
FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population Data presented at AACR show synergistic activity with FHD-909 in combination with pembrolizumab and KRAS inhibitors and support clinical exploration Selective CBP degrader on track for IND-enabling studies, targeting IND in 2026 Continued progress on Selective EP300 degrader and Selective ARID1B degrader with program updates expected in H2 2025 Strong balance sheet with cash, cash equivalents, and marketable securities of $220.6 million as of March 31, 2025 , provides cash runway into 2027 CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company's 10-Q filing for the quarter ended March 31, 2025. |
globenewswire.com |
2025-05-14 11:00:00 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference |
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Citizens Life Sciences Conference, being held May 7-8, 2025, in New York, NY. |
globenewswire.com |
2025-05-05 11:00:00 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors |
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors. |
globenewswire.com |
2025-05-01 11:00:00 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update |
- FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population |
globenewswire.com |
2025-04-28 20:05:00 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting |
Company to share new preclinical combination data for FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target population |
globenewswire.com |
2025-04-15 11:00:00 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting |
- FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population |
globenewswire.com |
2025-03-25 18:35:00 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates |
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.57 per share a year ago. |
zacks.com |
2025-03-06 21:05:21 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook |
First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population |
globenewswire.com |
2025-03-06 18:05:00 |
Czytaj oryginał (ang.) |
| Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know |
Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-27 13:06:12 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences |
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the B. Riley Securities Precision Oncology and Radiopharma Conference, and at the TD Cowen 45th Annual Health Care Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. |
globenewswire.com |
2025-02-25 09:00:00 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock? |
Foghorn Therapeutics (FHTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-02-11 12:26:10 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
Foghorn Therapeutics (FHTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2025-01-15 12:36:14 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know |
Foghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
zacks.com |
2025-01-09 15:01:18 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities |
Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy threshold not achieved to support continued development by Foghorn alone |
globenewswire.com |
2024-12-16 09:00:00 |
Czytaj oryginał (ang.) |
| After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX) |
The heavy selling pressure might have exhausted for Foghorn Therapeutics (FHTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2024-12-12 12:36:11 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why |
Foghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-11-29 15:00:27 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High? |
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 104.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-11-25 12:56:24 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences |
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jefferies London Healthcare Conference, the 7th Annual Evercore HealthCONx Conference, and the Citi Global Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. |
globenewswire.com |
2024-11-12 09:54:00 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates |
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.34 per share a year ago. |
zacks.com |
2024-11-04 20:31:18 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update |
First patient dosed with first-in-class SMARCA2(BRM) selective inhibitor FHD-909 (LY4050784) in Phase 1 trial with primary target population in SMARCA4(BRG1) mutated NSCLC |
globenewswire.com |
2024-11-04 18:05:00 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors |
Primary target patient population for the FHD-909 Phase 1 trial is non-small cell lung cancer (NSCLC) Lilly leads the clinical development of the Phase 1 trial Foghorn's selective SMARCA2 oncology program is part of a U.S. 50/50 co-development and co-commercialization collaboration with Lilly CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- October 10, 2024 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that the first patient has been dosed with FHD-909 (LY4050784) in the Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target patient population. |
globenewswire.com |
2024-10-10 11:00:00 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics to Participate in the BMO Oncology Summit |
CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in investor meetings at the BMO Oncology Summit being held Tuesday, October 8, 2024, in New York, NY. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. |
globenewswire.com |
2024-10-01 11:00:00 |
Czytaj oryginał (ang.) |
| Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength? |
Foghorn Therapeutics (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-09-16 09:15:34 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer |
CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Anna Rivkin, Ph.D., will join the company as Chief Business Officer (CBO), on September 3, 2024. Dr. Rivkin brings over two decades of expertise in a broad spectrum of complex business transactions across multiple disease areas. |
globenewswire.com |
2024-09-03 11:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet |
The consensus price target hints at an 81.2% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-09-02 14:55:44 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September |
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the 2024 Wells Fargo Healthcare Conference and presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. |
globenewswire.com |
2024-08-28 11:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 121.77%: Here's is How to Trade |
The consensus price target hints at a 121.8% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-08-16 14:55:15 |
Czytaj oryginał (ang.) |
| 5 Small Drug Stocks to Buy as Innovation Reaches Peak |
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio. |
zacks.com |
2024-08-16 13:20:29 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Tops Revenue Estimates |
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.70 per share a year ago. |
zacks.com |
2024-08-08 13:10:28 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update |
Topline Phase 1 dose escalation data for FHD-286 in combination with decitabine, in relapsed and/or refractory AML patients, anticipated in the fourth quarter of 2024 |
globenewswire.com |
2024-08-08 11:00:00 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June |
CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jefferies Global Healthcare Conference and the Goldman Sachs 45th Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. |
globenewswire.com |
2024-05-28 11:00:00 |
Czytaj oryginał (ang.) |
| Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline |
Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points |
globenewswire.com |
2024-05-22 22:21:00 |
Czytaj oryginał (ang.) |
| Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants |
CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (“Foghorn”) (Nasdaq: FHTX) today announced the pricing of a registered direct offering of 12,743,039 shares of its common stock at a price of $5.51 per share, before underwriting discounts and commissions, and in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 7,220,794 shares of its common stock at a price of $5.5099 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The offering is expected to close on or about May 22, 2024, subject to satisfaction of customary closing conditions. All of the shares of common stock in the offering are to be sold by Foghorn. |
globenewswire.com |
2024-05-20 11:58:00 |
Czytaj oryginał (ang.) |